{"ATC Code":"N03AX12","Abbreviation":"","Aliases":["Gabapentine","1-(Aminomethyl)cyclohexaneacetic acid","Aclonium","Gabapetin","Gabapentinum","gabapentina","Gabapentino","Fanatrex","Gralise","Serada"],"Biological Half-Life":"The elimination t\u003csub\u003e1/2\u003c/sub\u003e of gabapentin in patients with normal renal function is 5-7 hours. In patients with reduced renal function, the elimination t\u003csub\u003e1/2\u003c/sub\u003e may be prolonged - in patients with a creatinine clearance of \u003c30 mL/min, the reported half-life of gabapentin was approximately 52 hours.","CAS":"60142-96-3","ChEBI":"CHEBI:42797","ChEMBL":"CHEMBL940","ChemicalClasses":["gabapentinoid"],"Chirality":"achiral","Classes":null,"Color/Form":"White to off-white crystalline solid; crystals from ethanol/ether","Decomposition":"Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx).","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Antimanic Agents; GABA Agents","Drug Indication":"In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.","Drug Warnings":"VET: In general, avoid the use of the commercially available human oral solution (Neurontin) in dogs as it reportedly contains 300 mg/mL xylitol. As the threshold dose that can cause hypoglycemia in dogs is approximately 100 mg/kg doses of up to 15 mg/kg in dogs using the solution should be safe, but further data is needed to confirm this Additionally, xylitol may be hepatotoxic in dogs. Doses of 500 mg/kg of xylitol are thought to be the threshold for this toxicity, but there have been anecdotal reports of it occuring at much lower doss. In cats, at the dosages used presently, xylitol toxicity dosen not appear to be a problem with gabapentin oral solcuiton, but sue with caution.","DrugClasses":["calcium channel blocker"],"DurationOfAction":"","EINECS":"262-076-3","EliminationHalfLife":"5 - 7 hours","Erowid Experience Reports":[{"Id":"100429","Title":"Why Is It Called Frankenstein"},{"Id":"100496","Title":"Golden Bliss of the World"},{"Id":"100722","Title":"Waiting... Waiting... Oh Hi"},{"Id":"101418","Title":"For Me Goes Something Like This"},{"Id":"101550","Title":"Nice Mild High"},{"Id":"101501","Title":"Soothing High"},{"Id":"101645","Title":"Ego-Trippin"},{"Id":"102658","Title":"A Lovely Relaxed Day"},{"Id":"102823","Title":"Delirium"},{"Id":"102666","Title":"Saved Me From Tramadol Addiction"},{"Id":"103028","Title":"Boring, I Don't See Much Recreational Value"},{"Id":"102798","Title":"Helped With the Pain After About 1.5 Hours"},{"Id":"102980","Title":"Surprised at How Long the Effects Lasted"},{"Id":"102245","Title":"Yo Gaba Gaba"},{"Id":"102458","Title":"An Alcoholic's Alternative"},{"Id":"103840","Title":"CockBlocker"},{"Id":"104568","Title":"Good During Benzo Withdrawal"},{"Id":"106930","Title":"It's Like a Restart Button for My Brain"},{"Id":"107020","Title":"Beautifully Calming"},{"Id":"107007","Title":"Detached Calm"},{"Id":"106739","Title":"Everything in Its Place"},{"Id":"107771","Title":"The Day After, Mood Also Took a Hit"},{"Id":"108680","Title":"GabaGaba Good Time"},{"Id":"107957","Title":"For Alcohol Withdrawals"},{"Id":"108973","Title":"Can Make Me Feel a Little Shaky"},{"Id":"109658","Title":"Gaba Gaba Glorious"}],"European Community (EC) Number":"262-076-3","FDA Pharmacological Classification":"6CW7F3G59X","FullSalts":["Gabapentin hydrochloride","Gabapentin hydrobromide"],"HMDB ID":"HMDB0005015","HeavyAtomCount":12,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Antimanic Agents; GABA Agents","IUPACName":"2-[1-(aminomethyl)cyclohexyl]acetic acid","Impurities":["1-carboxycyclohexaneacetic acid","gabapentin lactam","(1-cyanocyclohexyl)acetic acid"],"InChI":"InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)","InChIKey":"UGJMXCAKCUNAIE-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)","Melting Point":"162-166 °C; also reported as 165-167 °C","MolecularFormula":"C\u003csub\u003e9\u003c/sub\u003eH\u003csub\u003e17\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"171.24 g/mol","Pharmacodynamics":"Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders. It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.  Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.","Physical Description":"Solid","PrevSalts":["hydrochloride","hydrobromide"],"PubChemId":3446,"Record Description":["Gabapentin is a gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome. It has a role as an anticonvulsant, a calcium channel blocker, an environmental contaminant and a xenobiotic. It is functionally related to a gamma-aminobutyric acid.","Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.. It is structurally and functionally related to another GABA derivative, [pregabalin].","The physiologic effect of gabapentin is by means of Decreased Central Nervous System Disorganized Electrical Activity.","Gabapentin is a unique anticonvulsant that is used as adjunctive therapy in management of epilepsy and for neuropathic pain syndromes. Therapy with gabapentin is not associated with serum aminotransferase elevations, but several cases of clinically apparent liver injury from gabapentin have been reported.","Gabapentin is a synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","GABAPENTIN is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 61 investigational indications.","Gabapentin was originally developed as a chemical analogue of gamma-aminobutyric acid (GABA) to reduce the spinal reflex for the treatment of spasticity and was found to have anticonvulsant activity in various seizure models. In addition, it also displays antinociceptive activity in various animal pain models. Clinically, gabapentin is indicated as an add-on medication for the treatment of partial seizures, and neuropathic pain. It was also claimed to be beneficial in several other clinical disorders such as anxiety, bipolar disorder, and hot flashes. The possible mechanisms or targets involved in the multiple therapeutic actions of gabapentin have been actively studied. Since gabapentin was developed, several hypotheses had been proposed for its action mechanisms. They include selectively activating the heterodimeric GABA(B) receptors consisting of GABA(B1a) and GABA(B2) subunits, selectively enhancing the NMDA current at GABAergic interneurons, or blocking AMPA-receptor-mediated transmission in the spinal cord, binding to the L-alpha-amino acid transporter, activating ATP-sensitive K(+) channels, activating hyperpolarization-activated cation channels, and modulating Ca(2+) current by selectively binding to the specific binding site of [(3)H]gabapentin, the alpha(2)delta subunit of voltage-dependent Ca(2+) channels. Different mechanisms might be involved in different therapeutic actions of gabapentin. In this review, we summarized the recent progress in the findings proposed for the antinociceptive action mechanisms of gabapentin and suggest that the alpha(2)delta subunit of spinal N-type Ca(2+) channels is very likely the analgesic action target of gabapentin. (A7831).","A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.","See also: Gabapentin Enacarbil (active moiety of).","Gabapentin is a gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome. It has a role as an anticonvulsant, a calcium channel blocker, an environmental contaminant and a xenobiotic. It is functionally related to a gamma-aminobutyric acid.","LiverTox|CNS|Anticonvulsant|GABA analogue"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Gabapentin","Name":"Gabapentin","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q410352","Name":"Gabapentin","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00996","Name":"Gabapentin","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3446","Name":"Gabapentin","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL940","Name":"Gabapentin","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:42797","Name":"Gabapentin","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=60142-96-3","Name":"Gabapentin","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005015","Name":"Gabapentin","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07018","Name":"Gabapentin","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6CW7F3G59X","Name":"Gabapentin","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0020074","Name":"Gabapentin","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3446, Gabapentin. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3446\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3446\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Gabapentin. UNII: 6CW7F3G59X. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6CW7F3G59X\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/6CW7F3G59X\u003c/a\u003e","Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed June 26, 2025. \u003ca href=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003ehttps://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003c/a\u003e"],"SMILES":"C1CCC(CC1)(CC(=O)O)CN","Salts":["hydrochloride","hydrobromide"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[1,1],"SaltsUNII":["N0PY5N5AFW","7PXD8ZD6PL"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"gov":"United States","ref":[],"schedule":"prescription only, schedule 5 in select states substance"}],"Solubility":"\u003e25.7 [ug/mL] (The mean of the results at pH 7.4)","Stability/Shelf Life":"Stable under recommended storage conditions.","StoreUNII":["6CW7F3G59X"],"StructureBase64":"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","Subjective Effects":null,"Taste":"Bitter","Therapeutic Uses":"Analgesics; Anti-Anxiety Agents; Anticonvulsants; Antimanic Agents; Antiparkinson Agents; Calcium Channel Blockers; Excitatory Amino Acid Antagonists","Title":"Gabapentin","UNII":"6CW7F3G59X","Wikidata":"Q410352","Wikipedia":"Gabapentin","XLogP":-1.1}